{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:14:43Z","timestamp":1778717683407,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["CRG\/2021\/004281"],"award-info":[{"award-number":["CRG\/2021\/004281"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["EMR\/2017\/003880"],"award-info":[{"award-number":["EMR\/2017\/003880"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004330","name":"Smoking Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["SR\/FST\/LSI-649\/2015"],"award-info":[{"award-number":["SR\/FST\/LSI-649\/2015"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009053","name":"The Wellcome Trust DBT India Alliance","doi-asserted-by":"publisher","award":["IA\/S\/17\/1\/503118"],"award-info":[{"award-number":["IA\/S\/17\/1\/503118"]}],"id":[{"id":"10.13039\/501100009053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009053","name":"The Wellcome Trust DBT India Alliance","doi-asserted-by":"publisher","award":["IA\/S\/15\/1\/501842"],"award-info":[{"award-number":["IA\/S\/15\/1\/501842"]}],"id":[{"id":"10.13039\/501100009053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.leukres.2023.107054","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T21:23:45Z","timestamp":1677792225000},"page":"107054","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines"],"prefix":"10.1016","volume":"128","author":[{"given":"Raveen Stephen Stallon","family":"Illangeswaran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Zechariah Paul","family":"Jebanesan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kezia Kanimozhi","family":"Sivakumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakhi Thalayattu","family":"Vidhyadharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharathi M.","family":"Rajamani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy Beryl","family":"Janet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest","family":"David","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaji Ramachandran","family":"Velayudhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9443-439X","authenticated-orcid":false,"given":"Poonkuzhali","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.leukres.2023.107054_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J."},{"issue":"12","key":"10.1016\/j.leukres.2023.107054_bib2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2023.107054_bib3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","article-title":"Treatment of relapsed acute myeloid leukemia","volume":"21","author":"Thol","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.leukres.2023.107054_bib4","unstructured":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia | NEJM [Internet]. [cited 2022 Oct 20]. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2012971."},{"issue":"12","key":"10.1016\/j.leukres.2023.107054_bib5","first-page":"1911","article-title":"Internal tandem duplication of the flt3 gene found in acute myeloid leukemia","volume":"10","author":"Nakao","year":"1996","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.leukres.2023.107054_bib6","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"7","key":"10.1016\/j.leukres.2023.107054_bib7","doi-asserted-by":"crossref","first-page":"926","DOI":"10.6004\/jnccn.2017.0116","article-title":"Acute Myeloid Leukemia, Version 3.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"O\u2019Donnell","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"issue":"11","key":"10.1016\/j.leukres.2023.107054_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cells9112493","article-title":"Molecular mechanisms of resistance to FLT3 inhibitors in acute myeloid leukemia: ongoing challenges and future treatments","volume":"9","author":"Scholl","year":"2020","journal-title":"Cells"},{"issue":"24","key":"10.1016\/j.leukres.2023.107054_bib9","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1200\/JCO.2010.28.5031","article-title":"Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data","volume":"28","author":"Mathews","year":"2010","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2023.107054_bib10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ccr.2010.06.003","article-title":"PML\/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3","volume":"18","author":"Jeanne","year":"2010","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.leukres.2023.107054_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N. Engl. J. Med"},{"issue":"22","key":"10.1016\/j.leukres.2023.107054_bib12","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2014-11-611459","article-title":"Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells","volume":"125","author":"Martelli","year":"2015","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.leukres.2023.107054_bib13","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1182\/blood-2012-01-402578","article-title":"Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide","volume":"120","author":"Goussetis","year":"2012","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.leukres.2023.107054_bib14","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1182\/bloodadvances.2019000540","article-title":"Retinoic acid synergizes with the unfolded protein response and oxidative stress to induce cell death in FLT3-ITD+ AML","volume":"3","author":"Masciarelli","year":"2019","journal-title":"Blood Adv."},{"issue":"22","key":"10.1016\/j.leukres.2023.107054_bib15","article-title":"Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells","volume":"125","author":"H EH","year":"2022","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.leukres.2023.107054_bib16","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2005.03.9503","article-title":"Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study","volume":"24","author":"Vey","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.leukres.2023.107054_bib17","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.leukres.2003.12.012","article-title":"Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and\/or newly diagnosed patients at least 65 years old","volume":"28","author":"Parmar","year":"2004","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.leukres.2023.107054_bib18","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12935-020-01341-5","article-title":"Arsenic trioxide potentiates Gilteritinib-induced apoptosis in FLT3-ITD positive leukemic cells via IRE1a-JNK-mediated endoplasmic reticulum stress","volume":"20","author":"Hu","year":"2020","journal-title":"Cancer Cell Int."},{"issue":"9","key":"10.1016\/j.leukres.2023.107054_bib19","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1158\/1535-7163.MCT-17-0298","article-title":"Arsenic trioxide and sorafenib induce synthetic lethality of FLT3-ITD acute myeloid leukemia cells","volume":"17","author":"Wang","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.leukres.2023.107054_bib20","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00277-013-1821-2","article-title":"ABCB6 RNA expression in leukemias--expression is low in acute promyelocytic leukemia and FLT3-ITD-positive acute myeloid leukemia","volume":"93","author":"Abraham","year":"2014","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2023.107054_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/bjc.1991.234","article-title":"1-beta-D-arabinofuranosylcytosine (Ara-C) enhances mitochondrial activities in human leukaemic cells","volume":"64","author":"Muus","year":"1991","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.leukres.2023.107054_bib22","first-page":"42","article-title":"Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells","volume":"33","author":"Kumar","year":"2014","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"issue":"6","key":"10.1016\/j.leukres.2023.107054_bib23","first-page":"1259","article-title":"Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1\/CIP1\/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis","volume":"59","author":"Wang","year":"1999","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.leukres.2023.107054_bib24","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood.V97.12.3931","article-title":"Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis","volume":"97","author":"Sordet","year":"2001","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2023.107054_bib25","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1182\/blood-2007-05-092510","article-title":"Internal tandem duplication of FLT3 (FLT3\/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML","volume":"111","author":"Sallmyr","year":"2008","journal-title":"Blood"},{"issue":"9_Supplement","key":"10.1016\/j.leukres.2023.107054_bib26","first-page":"5260","article-title":"Internal tandem duplication of FLT3 induces increased ROS production, DNA damage and misrepair: implications for RAC1-STAT5 function in genomic instability in myeloid malignancies","volume":"67","author":"Datta","year":"2007","journal-title":"Cancer Res."},{"issue":"43","key":"10.1016\/j.leukres.2023.107054_bib27","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.leukres.2023.107054_bib28","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s00277-022-04920-w","article-title":"Molecular characterization of triple-negative myeloproliferative neoplasms by next-generation sequencing","volume":"101","author":"Maddali","year":"2022","journal-title":"Ann. Hematol."},{"issue":"8","key":"10.1016\/j.leukres.2023.107054_bib29","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2217\/pgs.15.44","article-title":"RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia","volume":"16","author":"Abraham","year":"2015","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.leukres.2023.107054_bib30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/1471-2105-15-293","article-title":"jvenn: an interactive Venn diagram viewer","volume":"15","author":"Bardou","year":"2014","journal-title":"BMC Bioinforma."},{"key":"10.1016\/j.leukres.2023.107054_bib31","doi-asserted-by":"crossref","first-page":"W566","DOI":"10.1093\/nar\/gkv468","article-title":"ClustVis: a web tool for visualizing clustering of multivariate data using principal component analysis and heatmap","volume":"43","author":"Metsalu","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"24","key":"10.1016\/j.leukres.2023.107054_bib32","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1001\/jama.2010.1862","article-title":"A LEukemic Stem Cell Gene Expression Signature Is Associated with Clinical Outcomes in Acute Myeloid Leukemia","volume":"304","author":"Gentles","year":"2010","journal-title":"JAMA J. Am. Med Assoc."},{"key":"10.1016\/j.leukres.2023.107054_bib33","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41467-020-20717-9","article-title":"Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells","volume":"12","author":"Larrue","year":"2021","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.leukres.2023.107054_bib34","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/nm.2415","article-title":"Stem cell gene expression programs influence clinical outcome in human leukemia","volume":"17","author":"Eppert","year":"2011","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.leukres.2023.107054_bib35","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.leukres.2005.02.015","article-title":"Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patients","volume":"29","author":"Perea","year":"2005","journal-title":"Leuk. Res."},{"issue":"7","key":"10.1016\/j.leukres.2023.107054_bib36","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1158\/2159-8290.CD-16-0441","article-title":"Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism","volume":"7","author":"Farge","year":"2017","journal-title":"Cancer Discov."},{"issue":"21","key":"10.1016\/j.leukres.2023.107054_bib37","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2018-12-889725","article-title":"NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML","volume":"133","author":"Sasca","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2023.107054_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-019-1626-x","article-title":"Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine","volume":"10","author":"Levin","year":"2019","journal-title":"Cell Death Dis."},{"issue":"11","key":"10.1016\/j.leukres.2023.107054_bib39","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1038\/s43018-021-00264-y","article-title":"Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia","volume":"2","author":"Bosc","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.leukres.2023.107054_bib40","unstructured":"The Glycolytic Gatekeeper PDK1 defines different metabolic states between genetically distinct subtypes of human acute myeloid leukemia | Nature Communications [Internet]. [cited 2022 Oct 20]. Available from: https:\/\/www.nature.com\/articles\/s41467-022-28737-3."},{"issue":"4","key":"10.1016\/j.leukres.2023.107054_bib41","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1947601911409738","article-title":"The Role of p53 in metabolic regulation","volume":"2","author":"Puzio-Kuter","year":"2011","journal-title":"Genes Cancer"},{"issue":"34","key":"10.1016\/j.leukres.2023.107054_bib42","doi-asserted-by":"crossref","first-page":"23780","DOI":"10.18632\/oncotarget.25267","article-title":"p53 and metabolism: from mechanism to therapeutics","volume":"9","author":"Simabuco","year":"2018","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.leukres.2023.107054_bib43","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/s41375-020-0710-7","article-title":"Low frequency TP53 hotspot mutation contributes to chemoresistance through clonal expansion in acute myeloid leukemia","volume":"34","author":"Yan","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.leukres.2023.107054_bib44","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/1878-0261.12916","article-title":"Doxorubicin-induced senescence promotes stemness and tumorigenicity in EpCAM\u2212\/CD133\u2212 nonstem cell population in hepatocellular carcinoma cell line, HuH-7","volume":"15","author":"Karabicici","year":"2021","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.leukres.2023.107054_bib45","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.omto.2020.05.012","article-title":"DCLK1 regulates tumor stemness and cisplatin resistance in non-small cell lung cancer via ABCD-Member-4","volume":"18","author":"Panneerselvam","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"issue":"7","key":"10.1016\/j.leukres.2023.107054_bib46","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/cdd.2014.31","article-title":"Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy","volume":"21","author":"Auffinger","year":"2014","journal-title":"Cell Death Differ."},{"issue":"4","key":"10.1016\/j.leukres.2023.107054_bib47","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41375-018-0279-6","article-title":"Histone deacetylase inhibitor targets CD123\/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia","volume":"33","author":"Yan","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.leukres.2023.107054_bib48","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ccell.2018.08.007","article-title":"Identification of chemotherapy-induced leukemic-regenerating cells reveals a transient vulnerability of human AML recurrence","volume":"34","author":"Boyd","year":"2018","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.leukres.2023.107054_bib49","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1038\/s41375-022-01573-6","article-title":"Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia","volume":"36","author":"Pardieu","year":"2022","journal-title":"Leukemia"}],"updated-by":[{"DOI":"10.1016\/j.leukres.2023.107329","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000}}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623000395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623000395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:05:34Z","timestamp":1778717134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212623000395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":49,"alternative-id":["S0145212623000395"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107054","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapeutic drugs elicit stemness and metabolic alteration to mediate acquired drug-resistant phenotype in acute myeloid leukemia cell lines","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107054"}}